IRCT20200105046010N52招募中未知
In- Vivo Bioequivalence study of Tenofovir Alafenamide tablets 25 mg (Sobhan Trade Co, Iran) with brand drug (Vemlidy® 25 mg, Gilead, Canada) in Iranian healthy volunteers.
Sobhan Trade Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index between18-28
- •Informed consent
- •Being at the age of 18-55 years old
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
已完成
2 期
Clinical trial study on the therapeutic effect of Tenofovir besides routine drug regime (standard of care) in patients with Coronavirus disease 2019 (COVID-19)covid-19.Covid-19, confirmed cases, positive test resultU07.1IRCT20200422047168N1Ahvaz University of Medical Sciences60
招募中
不适用
In-vivo Bioequivalence Test of Favipiravir® tablet with brand drugs (AVIGAN® 200mgTAYOMA Chemical Ind. Co).IRCT20200105046010N30ABIDI Pharmaceutical Company24
已完成
4 期
The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy VolunteersHealthyNCT00862823University of Alabama at Birmingham14
进行中（未招募）
1 期
CLINICAL TRIAL WITH TENOFOVIR VERSUS LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL IN LAMIVUDINE-RESISTANT CHRONIC HEPATITIS-B PATIENTS WITH UNDETECTABLE VIRAL LOADCHRONIC HEPATITIS BMedDRA version: 14.0Level: LLTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-000629-55-ESManuel Rodríguez García100
招募中
不适用
In-vivo Bioequivalence Test of Teriflunomide® tablet with brand drugs (AUBAGIO® 14 mg Genzyme, Germany).IRCT20200105046010N25Aburayhan Pharmaceutical Company24